BioCryst Pharmaceuticals
BCRX
BCRX
116 hedge funds and large institutions have $380M invested in BioCryst Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 44 increasing their positions, 29 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
47% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 32
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
54% less capital invested
Capital invested by funds: $826M → $380M (-$446M)
Holders
116
Holding in Top 10
2
Calls
$4.84M
Puts
$4.86M
Top Buyers
| 1 | +$21M | |
| 2 | +$11.9M | |
| 3 | +$8.47M | |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$7.58M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$6.41M |
Top Sellers
| 1 | -$70.5M | |
| 2 | -$48.5M | |
| 3 | -$25.2M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$10.1M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$5.7M |